These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 10871153)

  • 1. CMV antigenemia following bone marrow transplantation: risk factors and outcomes.
    Osarogiagbon RU; Defor TE; Weisdorf MA; Erice A; Weisdorf DJ
    Biol Blood Marrow Transplant; 2000; 6(3):280-8. PubMed ID: 10871153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced risk of persisting cytomegalovirus pp65 antigenemia and cytomegalovirus interstitial pneumonia following allogeneic PBSCT.
    Trenschel R; Ross S; Hüsing J; Ottinger H; Elmaagacli A; Roggendorf M; Schaefer UW; Runde V
    Bone Marrow Transplant; 2000 Mar; 25(6):665-72. PubMed ID: 10734302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of cytomegalovirus antigenemia and shell vial culture in allogeneic marrow transplantation recipients receiving ganciclovir prophylaxis.
    Nicholson VA; Whimbey E; Champlin R; Abi-Said D; Przepiorka D; Tarrand J; Chan K; Bodey GP; Goodrich JM
    Bone Marrow Transplant; 1997 Jan; 19(1):37-41. PubMed ID: 9012929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of CMV disease in allogeneic BMT recipients by cytomegalovirus antigenemia-guided preemptive ganciclovir therapy.
    Koehler M; St George K; Ehrlich GD; Mirro J; Neudorf SM; Rinaldo C
    J Pediatr Hematol Oncol; 1997; 19(1):43-7. PubMed ID: 9065718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomised trial comparing cytomegalovirus antigenemia assay vs screening bronchoscopy for the early detection and prevention of disease in allogeneic bone marrow and peripheral blood stem cell transplant recipients.
    Humar A; Lipton J; Welsh S; Moussa G; Messner H; Mazzulli T
    Bone Marrow Transplant; 2001 Sep; 28(5):485-90. PubMed ID: 11593322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased incidence of cytomegalovirus (CMV) infection and CMV-associated disease after allogeneic bone marrow transplantation from unrelated donors. The Fukuoka Bone Marrow Transplantation Group.
    Takenaka K; Gondo H; Tanimoto K; Nagafuji K; Fujisaki T; Mizuno S; Miyamoto T; Okamura T; Hayashi S; Eto T; Osaki K; Yamasaki K; Shibuya T; Harada N; Teshima T; Matsuishi E; Minematsu T; Minamishima Y; Harada M; Niho Y
    Bone Marrow Transplant; 1997 Feb; 19(3):241-8. PubMed ID: 9028553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surveillance of cytomegalovirus infections in bone marrow transplant in Trieste: seven years' experience.
    D'Agaro P; Andolina M; Burgnich P; Samar E; Campello C
    Haematologica; 2000 Nov; 85(11 Suppl):54-7. PubMed ID: 11268325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation.
    Burns LJ; Miller W; Kandaswamy C; DeFor TE; MacMillan ML; Van Burik JA; Weisdorf DJ
    Bone Marrow Transplant; 2002 Dec; 30(12):945-51. PubMed ID: 12476289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different kinetics in anti-cytomegalovirus immunity reconstitution evaluated by lymphocyte proliferation and IFN-gamma production in allogeneic and autologous bone marrow transplantation.
    Mendes AV; Benard G; Pereira CB; Kallas EG; Duarte AJ; Pannuti CS; Dulley FL; Machado CM
    Acta Haematol; 2002; 107(4):187-94. PubMed ID: 12053145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Graft-versus-leukaemia activity associated with CMV-seropositive donor, post-transplant CMV infection, young donor age and chronic graft-versus-host disease in bone marrow allograft recipients. The Nordic Bone Marrow Transplantation Group.
    Jacobsen N; Badsberg JH; Lönnqvist B; Ringdén O; Volin L; Rajantie J; Nikoskelainen J; Keiding N
    Bone Marrow Transplant; 1990 Jun; 5(6):413-8. PubMed ID: 2164434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytomegalovirus infection in recipients of related and unrelated donor bone marrow transplants: no evidence of increased incidence in patients receiving unrelated donor grafts.
    Foot AB; Pamphilon D; Caul EO; Roome AP; Hunt LP; Cornish JM; Oakhill A
    Br J Haematol; 1998 Aug; 102(3):671-7. PubMed ID: 9722292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of cytomegalovirus infection on 1-year mortality rates among recipients of allogeneic bone marrow transplants.
    Humar A; Wood S; Lipton J; Messner H; Meharchand J; McGeer A; MacDonald K; Mazzulli T
    Clin Infect Dis; 1998 Mar; 26(3):606-10. PubMed ID: 9524831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CMV prophylaxis with foscarnet in allogeneic bone marrow transplant recipients at high risk of developing CMV infections.
    Bacigalupo A; Tedone E; Van Lint MT; Trespi G; Lonngren M; Sanna MA; Moro F; Frassoni F; Occhini D; Gualandi F
    Bone Marrow Transplant; 1994 Jun; 13(6):783-8. PubMed ID: 7920315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical utility of CMV surveillance cultures and antigenemia following bone marrow transplantation.
    Humar A; O'Rourke K; Lipton J; Messner H; Meharchand J; Mahony J; Walker I; Wasi P; McGeer A; Moussa G; Chua R; Mazzulli T
    Bone Marrow Transplant; 1999 Jan; 23(1):45-51. PubMed ID: 10037050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of allogeneic bone marrow transplant recipients at risk for cytomegalovirus disease using a surveillance bronchoscopy and prolonged pre-emptive ganciclovir therapy.
    Reddy V; Hao Y; Lipton J; Meharchand J; Minden M; Mazzulli T; Chan C; Messner HA
    J Clin Virol; 1999 Aug; 13(3):149-59. PubMed ID: 10443791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytomegalovirus infection after allogeneic transplantation: comparison of cord blood with peripheral blood and marrow graft sources.
    Walker CM; van Burik JA; De For TE; Weisdorf DJ
    Biol Blood Marrow Transplant; 2007 Sep; 13(9):1106-15. PubMed ID: 17697973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytomegalovirus diagnosis in renal and bone marrow transplant recipients: the impact of molecular assays.
    Halwachs-Baumann G; Wilders-Truschnig M; Enzinger G; Eibl M; Linkesch W; Dornbusch HJ; Santner BI; Marth E; Kessler HH
    J Clin Virol; 2001 Jan; 20(1-2):49-57. PubMed ID: 11163583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Requirements for early discharge after allogeneic bone marrow transplantation].
    Yasumi M; Karasuno T; Kanashima H; Masaie H; Taniguchi H; Mitsui H; Nakamura H; Hiraoka A
    Rinsho Ketsueki; 2001 Aug; 42(8):601-9. PubMed ID: 11579498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytomegalovirus infection in children who underwent hematopoietic stem cell transplantation at a single center: a retrospective study of the risk factors.
    Yoon HS; Lee JH; Choi ES; Seo JJ; Moon HN; Kim MN; Im HJ
    Pediatr Transplant; 2009 Nov; 13(7):898-905. PubMed ID: 19032414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of cytomegalovirus (CMV) viremia using the pp65 antigenemia assay, the amplicor CMV test, and a semi-quantitative polymerase chain reaction test after allogeneic marrow transplantation.
    Ksouri H; Eljed H; Greco A; Lakhal A; Torjman L; Abdelkefi A; Ben Othmen T; Ladeb S; Slim A; Zouari B; Abdeladhim A; Ben Hassen A
    Transpl Infect Dis; 2007 Mar; 9(1):16-21. PubMed ID: 17313466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.